We showed that AKT1 E17K-mutated meningiomas have a less immunosuppressive tumour microenvironment when compared to grade I NF2 meningiomas; this may explain why some NF2 tumours have high progression/recurrence rates. This evidence concerns the gene AKT1 and meningioma.